Using a smartphone app to improve quality of life for cancer patients
Effects in Quality of Life of a Telemonitoring Platform Amongst Patients With Cancer: A Randomized Trial
This study tests whether using a smartphone app can help improve the quality of life for adults recently diagnosed with cancer compared to regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universidad Nacional Andres Bello Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Santiago) |
| Trial ID | NCT06086990 on ClinicalTrials.gov |
What this trial studies
This interventional study investigates the effectiveness of a smartphone application called Contigo in enhancing the quality of life for patients with various types of cancer compared to standard care. The study will randomly assign 80 adults with recent cancer diagnoses to either use the app or receive standard educational care. It aims to assess changes in quality of life, depressive symptoms, and adherence to medical appointments through validated questionnaires. The app provides monitoring and educational resources to help patients manage their condition effectively.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with a recent histologically confirmed diagnosis of specific cancers who are about to start curative treatment.
Not a fit: Patients with sensory or cognitive impairments that hinder app usage may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly improve the quality of life for cancer patients by providing them with better support and resources.
How similar studies have performed: Other studies have shown promising results with telemonitoring approaches in improving patient outcomes, suggesting potential success for this novel application.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients (\>18 years old). * Recent histologically confirmed diagnosis (within the last 3 months) of bronchogenic, breast, gallbladder, gastric, colorectal, or prostate cancer in any of its forms. * Awaiting initiation of curative intent treatment for the disease using any modality (radiation therapy, chemotherapy, immunotherapy, etc.) at the UC-Christus Cancer Center. * Possession of a smartphone, regardless of its native operating system (iOS® or Android®). * Willingness to sign an informed consent form to participate in the study. Exclusion Criteria: * Any form of sensory impairment preventing app usage. * Cognitive impairment. * Psychiatric pathology hindering app usage. * Unwillingness to participate in the study. * Concurrent participation in another clinical trial addressing healthcare technologies.
Where this trial is running
Santiago
- UC Christus Cancer Centre — Santiago, Chile (Recruiting)
Study contacts
- Principal investigator: Manuel Gonzalez, PhD — Pontificia Universidad Catolica de Chile
- Study coordinator: Felipe T Martinez, MD, MSc
- Email: felipe.martinez.l@unab.cl
- Phone: 999690952
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.